Answers are grounded in this paper and cite their sources.
OBJECTIVE: To examine the frequency and cost of orbital decompression in Australia over a 20-year period and estimate the incidence of thyroid eye disease (TED) using orbital decompression data. DESIGN: Retrospective population-based study. PARTICIPANTS: Individuals undergoing orbital decompression in Australia from July 2002 to June 2022, identified using the National Hospital Morbidity and Medicare databases. METHODS: Annual orbital decompression rates (Poisson regression) were calculated, overall and by sex. RESULTS: Of the 2661 orbital decompressions performed during the study period, most were for individuals aged 45-64 years (49.6%) and females (68.0%, female:male ratio 2.1:1). From 2002-2003 to 2021-2022, annual orbital decompression rates fluctuated but overall increased 1.6-fold (58.1%), from 3.7 to 5.8 surgeries per 1 000 000, respectively. Annual decompression rates stabilized during 2011-2022. During 2002-2022, annual decompression rates were greater in females than in males (mean, 7.9 vs 3.7 surgeries per 1 000 000). The estimated mean annual procedural cost associated with orbital decompression was AU$2.4 million. Over 20 years, the estimated annual incidence of TED was 7.2 per 100 000, greater in females than in males (9.8 vs 4.7 per 100 000). CONCLUSIONS: Orbital decompression rates increased in Australia over 20 years, stabilizing in the last decade. Decompression had a significant cost burden. These data provide a useful baseline for comparison in future studies. Decompression rates and TED incidence may vary further as novel immune-modulating therapies for Graves disease and TED, such as teprotumumab, become available in Australia.
No takes yet. Share an insight, caveat, or question.
Phakey et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: